Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Zendy

James Larkin | Zendy; Vanna ChiarionSileni | Zendy; René González | Zendy; JeanJacques Grob | Zendy; Piotr Rutkowski | Zendy; Christopher D. Lao | Zendy; C. Lance Cowey | Zendy; Dirk Schadendorf | Zendy; John Wagstaff | Zendy; Reinhard Dummer | Zendy; Pier Francesco Ferrucci | Zendy; Michael Smylie | Zendy; David Hogg | Zendy; Andrew F. Hill | Zendy; Iván MárquezRodas | Zendy; John B.A.G. Haanen | Zendy; Massimo Guidoboni | Zendy; Michele Maio | Zendy; Patrick Schöffski | Zendy; Matteo S. Carlino | Zendy; Célèste Lebbé | Zendy; Grant A. McArthur | Zendy; Paolo A. Ascierto | Zendy; Gregory A. Daniels | Zendy; Georgina V. Long | Zendy; Lars Bastholt | Zendy; Jasmine I. Rizzo | Zendy; Ágnes Balogh | Zendy; Andriy Moshyk | Zendy; F. Stephen Hodi | Zendy; Jedd D. Wolchok | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Author(s) -

James Larkin,

Vanna ChiarionSileni,

René González,

JeanJacques Grob,

Piotr Rutkowski,

Christopher D. Lao,

C. Lance Cowey,

Dirk Schadendorf,

John Wagstaff,

Reinhard Dummer,

Pier Francesco Ferrucci,

Michael Smylie,

David Hogg,

Andrew F. Hill,

Iván MárquezRodas,

John B.A.G. Haanen,

Massimo Guidoboni,

Michele Maio,

Patrick Schöffski,

Matteo S. Carlino,

Célèste Lebbé,

Grant A. McArthur,

Paolo A. Ascierto,

Gregory A. Daniels,

Georgina V. Long,

Lars Bastholt,

Jasmine I. Rizzo,

Ágnes Balogh,

Andriy Moshyk,

F. Stephen Hodi,

Jedd D. Wolchok

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1910836

Subject(s) - nivolumab , ipilimumab , medicine , melanoma , oncology , metastatic melanoma , overall survival , immunotherapy , cancer , cancer research

Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research